Latest Medicine stories from Life.
In a notable shift from previous GOP stances, the Trump administration is now supporting research into psychedelics and reconsidering marijuana's legal status.
In a notable policy shift, President Trump has reclassified state-licensed medical marijuana as a less-dangerous drug, a change that advocates have long pursued.
Legislators in Colorado and Virginia are opposing efforts to limit the powers of prescription drug affordability boards, highlighting a significant debate over drug pricing strategies.
Federal regulators are set to unveil a new Medicare coverage pathway aimed at accelerating access to FDA-designated breakthrough medical devices, enhancing treatment options for patients.
In a recent shift, RFK Jr. has expressed support for vaccinations while also defending his previous secret agreements with pharmaceutical companies.
The Nuclear Energy Agency (NEA) recently convened a workshop to explore advancements and challenges in the supply of medical radioisotopes.
Stay informed with the latest developments in the biotech sector, featuring updates on RevMed, Roche, and Kyverna's CAR-T therapy.
Thomas Goetz emphasizes that each drug represents a broader narrative involving health, medicine, society, and economics.
Roche is advancing its experimental multiple sclerosis drug to regulators following successful trials, though significant safety concerns persist.
A judge is anticipated to impose a $225 million forfeiture on Purdue Pharma, the maker of OxyContin, facilitating the completion of its settlement with the Justice Department.
A U.S. judge is anticipated to order Purdue Pharma to forfeit $225 million, marking a significant step in ongoing legal proceedings.
A closer look at the ongoing disputes surrounding drug price transparency and the role of pharmacy benefit managers (PBMs) in this contentious issue.
In recent pharmaceutical news, Trump has shown support for psychedelic treatment options while discussions continue regarding the future of weight-loss drugs.
Recent findings suggest that prolonged use of a drug from Nektar Therapeutics may encourage hair growth in individuals suffering from alopecia.
Pharmacy benefit managers (PBMs) are opposing a significant proposal aimed at increasing transparency in drug pricing, claiming it may be illegal.
The American Association of Cancer Researchers' annual meeting showcases significant advancements in the development of KRAS-targeting therapies, particularly by Revolution Medicines.
Zai Lab and Amgen have announced a partnership to evaluate a new approach to lung cancer treatment, marking a significant step in cancer research.
The FDA has accepted Ultragenyx's Biologics License Application for its gene therapy UX111, aimed at treating Sanfilippo Syndrome.
The pancreatic cancer drug Daraxonrasib from Revolution Medicines is reportedly achieving remarkable results, with some patients experiencing doubled survival times.
Recent headlines may suggest a growing skepticism towards vaccines among Americans, but a new poll indicates that this perception may not reflect reality.